Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis

doi:10.12998/wjcc.v12.i24.5468

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (396)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

HTML

257

Figures (1-3)

Sum=352

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=29

Aug 26, 2024 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Cases. Aug 26, 2024; 12(24): 5468-5472
Published online Aug 26, 2024. doi: 10.12998/wjcc.v12.i24.5468

Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis

Jonathan Soldera

Jonathan Soldera, Acute Medicine and Gastroenterology, University of South Wales, Cardiff CF37 1DL, United Kingdom

Author contributions: Soldera J contributed to writing and reviewing the final draft of the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jonathan Soldera, MD, MSc, PhD, Executive Associate Editor-in-Chief, Instructor, Acute Medicine and Gastroenterology, University of South Wales, Llantwit Road, Pontypridd, Cardiff CF37 1DL, United Kingdom. jonathansoldera@gmail.com

Received: March 18, 2024
Revised: April 20, 2024
Accepted: May 17, 2024
Published online: August 26, 2024
Processing time: 115 Days and 8.4 Hours

Core Tip

Core Tip: This editorial explores the efficacy and safety of Janus kinase inhibitors, specifically upadacitinib and tofacitinib, in refractory ulcerative colitis (UC) and acute severe UC (ASUC). Highlighting a compelling case report, it underscores the potential of these small-molecule therapies, either alone or in combination with biologics, to achieve and maintain disease remission. Furthermore, it emphasizes the importance of considering overlapping infections in ASUC and the need for prompt recognition by colorectal surgeons. This editorial advocates for further research to refine treatment strategies for patients with treatment-resistant UC, shedding light on promising therapeutic approaches.